Antineuropathic effects of the antibiotic derivative spicamycin KRN5500.

Abstract

Excellence in neuropathic pain management continues to challenge the ability of health care providers. Current medications are helpful but often create significant side effects or simply fail to provide adequate analgesia. We report here on a serendipitous finding of the successful attenuation of neuropathic pain in a patient with long-standing monoclonal gammopathy, Raynaud's disease, and neuropathic pain who received the trial chemotherapeutic agent KRN5500. This finding led to animal studies that have provided support for the possible use of KRN5500 in the treatment of neuropathic pain in humans as well as some insight into the possible mechanism(s) of action of this drug.

• Authors: David Borsook, Annabel Davis Edwards
• Journal: Pain medicine (Malden, Mass.) (Pain Med) Vol. 5 Issue 1 Pg. 104-8 (Mar 2004) ISSN: 1526-2375 [Print] England
• PMID: 14996243 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright American Academy of Pain Medicine

Chemical References

• Analgesics
• Anti-Bacterial Agents
• Purine Nucleosides
• septacidin

Topics

• Aged
• Analgesics (administration & dosage)
• Anti-Bacterial Agents (administration & dosage)
• Humans
• Infusions, Intravenous
• Male
• Pain (drug therapy, pathology)
• Polyneuropathies (drug therapy, pathology)
• Purine Nucleosides (administration & dosage)
• Raynaud Disease (drug therapy, pathology)